POLITICO
Get the Prescription Pulse newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presented by Coalition for Affordable Prescription Drugs
With Emily Martin Congress waits on FDA pick as Senate readies for the first HHS confirmation hearing. FDA device panel meets today
to discuss drug-coated balloon.
It’s Wednesday, welcome back to Prescription Pulse. Welcome back from the long weekend! You ll still see us again on Friday too.
Legal Disclaimer
You are responsible for reading, understanding and agreeing to the National Law Review s (NLR’s) and the National Law Forum LLC s Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.
Parkinson s
Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson s Disease (PD). Adaptive deep brain stimulation is an investigational feature of the Percept™ PC device that could be enabled if approved. The investigational feature used in this study allows for automated adjustment of brain stimulation to provide therapy to manage symptoms of Parkinson s disease based on a patient s clinical state.
The randomized study will take place across 12 study sites at leading Movement Disorders research centers in the United States, Europe, and Canada. An estimated 36 subjects will undergo a total evaluation period of 15 months. The primary endpoint of ADAPT-PD will compare standard continuous DBS (cDBS) to aDBS for hours of On time without troublesome dyskinesias, a measure of treatment efficacy versus side effects, as reported by patient diary. Qualifying subjects in the study will receive cDBS at baseline follo
Global Bioengineered Skin Substitutes Market to Reach $4.33 Billion by 2030
The bioengineered skin substitutes market is currently at a blooming phase, with the presence of various juggernauts such as AbbVie, Inc., Integra LifeSciences Corporation, Smith & Nephew plc, and Stryker Corporation, and other medium and small-medium enterprises that are offering a wide range of bioengineered skin substitutes products in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.
Technological advancements in wound biologics coupled with innovations in the field of tissue engineering have led to the development of advanced wound healing options and strategies, including bioengineered skin substitutes. These products are being designed to treat a wide range of acute and chronic wounds that pose a serious healthcare threat g